Daniel R. Zwahlen

Kantonsspital Winterthur

Papers

1

Total Citations

3

H-Index

1

About

Dr. Daniel R. Zwahlen is a leading radiation oncologist whose research focuses on optimizing stereotactic body radiotherapy (SBRT) for prostate cancer, particularly through fractionation schedule comparisons. His most impactful work, a 2023 propensity score matched pair analysis, directly compared five-fraction versus seven-fraction SBRT regimens in intermediate- and high-risk prostate cancer patients. This study, which has garnered early attention with 3 citations, provides critical evidence on balancing treatment efficacy with toxicity profiles, helping to refine clinical protocols for non-invasive cancer management. Dr. Zwahlen’s contributions are central to advancing personalized radiotherapy, reducing treatment burden while maintaining tumor control. His research addresses a key question in modern oncology: how to shorten radiation courses without compromising safety or outcomes. By leveraging retrospective data from multiple institutions, he bridges the gap between clinical practice and evidence-based guidelines. Dr. Zwahlen’s work is essential reading for clinicians and researchers exploring dose escalation, hypofractionation, and the evolving landscape of prostate cancer radiotherapy.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Five Fractions versus Seven Fractions SBRT for Intermediate- and High-Risk Prostate Cancer: A Propensity Score Matched Pair Analysis
3 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Kantonsspital Winterthur

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago